1. Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.

    Oncotarget 5(18):8235 (2014) PMID 25249538 PMCID PMC4226680

    A present challenge in breast oncology research is to identify therapeutical targets which could impact tumor progression. Neurotensin (NTS) and its high affinity receptor (NTSR1) are up regulated in 20% of breast cancers, and NTSR1 overexpression was shown to predict a poor prognosis for 5 year...
  2. Resistance to human epidermal growth factor receptor type 2-targeted therapies.

    European Journal of Cancer 50(5):892 (2014) PMID 24462377

    The overexpression of the human epidermal growth factor receptor type 2 (HER-2) is an independent prognostic factor of poor outcome in patients with breast cancer. Two compounds have been registered for HER-2-positive tumour treatment: trastuzumab, a humanised antibody directed against the HER-2...
  3. [PAIR-gynaecology: multi/interdisciplinary for gynecologic cancer research. Problems needed to be resolved].

    Bulletin du cancer 99(4):479 (2012) PMID 22469552

    Each year, 13,000 newly gynecologic cancers are diagnosed in France. Gynecologic cancers were specifically heterogeneous (localisations, histologic subgroups, age class, etc). This work was delineated for a national call dedicated to gynecologic cancers. This review reports the major needs in te...
  4. Prognostic value of isolated tumor cells and micrometastases of lymph nodes in early-stage breast cancer: A French sentinel node multicenter cohort study

    The Breast 23(5) (2005) PMID 24874284

    To define the prognostic value of isolated tumor cells (ITC), micrometastases (pN1mi) and macrometastases in early stage breast cancer (ESBC). We conducted a retrospective multicenter cohort study at 13 French sites. All the eligible patients who underwent SLNB from January 1...